Cargando…

Bell Shape Curves of Hemolysis Induced by Silver Nanoparticles: Review and Experimental Assay

The hemolytic activity assay is a versatile tool for fast primary toxicity studies. This work presents a systematic study of the hemolytic properties of Argovit(TM) silver nanoparticles (AgNPs) extensively studied for biomedical applications. The results revealed an unusual and unexpected bell-shape...

Descripción completa

Detalles Bibliográficos
Autores principales: Luna-Vázquez-Gómez, Roberto, Arellano-García, María Evarista, Toledano-Magaña, Yanis, García-Ramos, Juan Carlos, Radilla-Chávez, Patricia, Salas-Vargas, David Sergio, Casillas-Figueroa, Francisco, Ruiz-Ruiz, Balam, Pestryakov, Alexey, Bogdanchikova, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000491/
https://www.ncbi.nlm.nih.gov/pubmed/35407184
http://dx.doi.org/10.3390/nano12071066
Descripción
Sumario:The hemolytic activity assay is a versatile tool for fast primary toxicity studies. This work presents a systematic study of the hemolytic properties of Argovit(TM) silver nanoparticles (AgNPs) extensively studied for biomedical applications. The results revealed an unusual and unexpected bell-shaped hemolysis curve for human healthy and diabetic donor erythrocytes. With the decrease of pH from 7.4 and 6.8 to 5.6, the hemolysis profiles for AgNPs and AgNO(3) changed dramatically. For AgNPs, the bell shape changed to a step shape with a subsequent sharp increase, and for AgNO(3) it changed to a gradual increase. Explanations of these changes based on the aggregation of AgNPs due to the increase of proton concentration were suggested. Hemolysis of diabetic donor erythrocytes was slightly higher than that of healthy donor erythrocytes. The meta-analysis revealed that for only one AgNPs formulation (out of 48), a bell-shaped hemolysis profile was reported, but not discussed. This scarcity of data was explained by the dominant goal of studies consisting in achieving clinically significant hemolysis of 5–10%. Considering that hemolysis profiles may be bell-shaped, it is recommended to avoid extrapolations and to perform measurements in a wide concentration interval in hemolysis assays.